AQUILON PHARMACEUTICALS
Board
7 directors, last change in 2025Independent director
since 13-02-2023
6-year term from 2023
listed in the 2025 annual accounts, filed on 22-07-2026
Class D director
since 13-02-2023
6-year term from 2023
listed in the 2025 annual accounts, filed on 22-07-2026
Director
since 04-06-2024
6-year term from 2024
listed in the 2025 annual accounts, filed on 22-07-2026
Director
since 04-06-2024
6-year term from 2024
listed in the 2025 annual accounts, filed on 22-07-2026
Maes PharmConsult Srl
Director, permanent representative Paul Maes
since 04-06-2024
6-year term from 2024
listed in the 2025 annual accounts, filed on 22-07-2026
Director, permanent representative Gauthier Van Der Elst
since 04-06-2024
6-year term from 2024
listed in the 2025 annual accounts, filed on 22-07-2026
Director
since 02-07-2025
6-year term from 2025
listed in the 2025 annual accounts, filed on 22-07-2026
- Signing authorityThe articles say who may bind the company, for example by signing a contract.
- “Le Conseil d’administration sera représenté à l’acte authentique soit par deux administrateurs agissant conjointement, conformément aux…”deed of 10-08-2026
Permanent representatives 2
Gauthier Van Der Elst
Permanent representative, for Scale I
in office according to the deed of 16-04-2025
Paul Maes
Permanent representative, for Maes PharmConsult Srl
in office according to the deed of 16-04-2025
Mandates through the years
11 names, the dashed line is todayDidier Cataldo
Director
Director
Maes PharmConsult Srl
Director
Director
Scale I
Director
Director
BENAMEUR Hassan
Independent director
Independent director
MANOR Moshe
Class D director
Class D director
Frank Pieters
Director
Director
Charles Nelles
Director
Director
Michael Mellink
Class B director
Class B director
DE GHELDERE Joseph
Director
Director
JEANMART Patrick
Director
Director
Sambrinvest spin-off/spin-out
Director
Director
BoardEarlierRest of the termmandate already running before its first mention
Mandates as a list
- Didier Cataldo
- Director, from 30-11-2018 to date
- Maes PharmConsult Srl
- Director, from 30-11-2018 to date
- Scale I
- Director, from 30-11-2018 to date
- BENAMEUR Hassan
- Independent director, since before 31-12-2022
- MANOR Moshe
- Class D director, since before 31-12-2022
- Frank Pieters
- Director, since before 04-06-2024
- Charles Nelles
- Director, from 02-07-2025 to date
- Michael Mellink
- Class B director, from before 31-12-2022 to 16-09-2025
- DE GHELDERE Joseph
- Director, from 30-11-2018 to 17-02-2023
- JEANMART Patrick
- Director, from 25-06-2019 to 17-02-2023
- Sambrinvest spin-off/spin-out
- Director, until 17-02-2023
Control
3.43%
This company
AQUILON PHARMACEUTICALS
Equity €4.3m
Loss €444,073 in 2025
Capital
- Capital
- €5,486,277.23
- Shares
- 273,646 in the deed of 04-07-2025 and 2 later capital increases
- Contribution per share
- €20.05
- Equity per share
- €15.55 in 2025
- Source
- 2025 annual accounts
Owners through the years
as the annual accounts name themOwners as a list
- Carbon Spin Off / Spin Out
- SCALE I
- P&L Projects
Source: lists of holdings in the owners' accounts
Articles of association
- Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
- Last Thursday of June at 16:00deed of 22-05-2025 (in French)
- Liquidation ruleIn a liquidation the creditors are paid first. What is left goes to the shareholders.
- “Sauf liquidation en un seul acte, par le Tribunal de l'Entreprise dans les cas prévus par la loi”deed of 19-07-2022 (in French)
Shareholders
2 ownersOwners 2
- Equity €662,782 Profit of €651,221 in 2025 (loss of €293,555 in 2024) Checked score 95Sourceaccounts SCALE I 20253.43%
- Equity €456,193 Loss of €15,876 in 2025 (profit of €25,615 in 2024) Checked score 820.45%
Capital transactions
Capital over time
- 10-08-2026 Capital increase · 3,000 new shares · in cash
- 10-08-2026 Capital increase of €412,884 · to €5,899,161.23 · 7,972 new shares · in-kind contribution of claims held by subscribers against the company
- 04-07-2025 Capital increase of €1,823,821.43 · to €5,936,277.23 · 39,516 new shares at €46.15 per share, 15% of the 262,674 shares after the increase · “apport de créances détenues par les souscripteurs à l’encontre de la société”
- 04-07-2025 Capital reduction of €450,000 · to €5,486,277.23 · to absorb losses
- 22-05-2025 Capital increase of €430,304 · to €3,646,398.84 · 15,368 new shares at €28 per share, 7.4% of the 206,500 shares after the increase · in cash
- 22-05-2025 Capital increase of €466,056.96 · to €4,112,455.80 · 16,658 new shares, 7.5% of the 223,158 shares after the increase · in kind
- 20-03-2025 Capital increase of €249,816 · to €2,766,104.65 · 8,922 new shares at €28 per share, 5.1% of the 174,881 shares after the increase
- 20-03-2025 Capital increase of €449,990.19 · to €3,216,094.84 · 16,251 new shares at €27.69 per share, 8.5% of the 191,132 shares after the increase
Show 6 older capital entries
- 23-12-2024 Capital increase of €346,893.46 · to €2,966,288.65 · 7,516 new shares at €46.15 per share, 4.5% of the 165,959 shares after the increase · “apport de créances détenues par les souscripteurs à l’encontre de la société”
- 23-12-2024 Capital reduction of €450,000 · to €2,516,288.65 · to absorb losses
- 14-11-2023 Capital increase of €348,278.08 · to €3,381,395.19 · 7,546 new shares at €46.15 per share, 4.8% of the 158,443 shares after the increase · “apport de créances détenues par les souscripteurs à l’encontre de la société”
- 14-11-2023 Capital reduction of €762,000 · to €2,619,395.19 · to absorb losses
- 17-02-2023 Capital reduction of €1,201,147.77 · to €1,523,235.16 · to absorb losses
- 17-02-2023 Capital increase of €1,509,881.95 · to €3,033,117.11 · 32,714 new shares at €46.15 per share, 21.7% of the 150,897 shares after the increase · “apport de créances détenues par souscripteurs à encontre société”